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A B S T R A C T
Background: Osteoporosis is currently a major cause of mortality, morbidity, and medical expense worldwide. Aim: This study was 
designed to detect the effect of raloxifene hydrochloride on bone mineral density (BMD) and serum lipids in Kuwaiti postmenopausal 
women with osteoporosis. Subjects and Methods: Eighty postmenopausal women, who received raloxifene 60 mg with calcium 
500 mg and 200 IU Vitamin D daily for 2 years were included in this prospective study which was conducted from August 2011 to 
August 2013 after informed consent and approval of the study by hospital ethical committee. BMD measured by dual‑energy X‑ray 
absorptiometry (DXA) and serum lipids were assessed before and after the treatment to detect the effect of raloxifene on BMD and on 
serum lipids. Unpaired t‑test was used to compare lumbar spine, total hip BMD and serum lipid values before and after the raloxifene 
treatment. Results: Lumbar spine and total hip BMD were significantly increased from 0.92 (3.8) and − 0.83 (5.6); respectively before 
treatment to 3.21 (5.4) and 1.62 (7.4); respectively 2 years after treatment. Also, Ward`s triangle and trochanter BMD were significantly 
increased from 1.53 (6.6) and − 1.4 (6.4); respectively to 4.84 (9.3) and 1.78 (8.5); respectively. Total cholesterol and low‑density 
lipoprotein cholesterol were significantly decreased from 5.15 (4.5) and 3.82 (4.6) mmol/L; respectively before treatment to 3.57 (3.4) 
and 2.56 (3.7) mmol/L; respectively 2 years after treatment. While, changes in high‑density lipoprotein cholesterol and triglycerides 
after treatment were statistically insignificant. Conclusions: Raloxifene appears to be an effective, well tolerated option for treating 
osteoporosis in Kuwaiti postmenopausal women, suitable for long term use with favorable effect on serum lipid profiles.
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INTRODUCTION
Reduced estrogen in postmenopausal women accelerates 
bone loss and estrogen replacement therapy can prevent 
bone loss.[1‑3] Long‑term estrogen use (without concurrent 
use of progestin) has been reported to cause an increased risk 
of endometrial cancer.[4,5] Raloxifene hydrochloride is one of 
estrogen receptor modulator acting as an estrogen agonist in 
bone and as antagonist in breast and uterus.[6] Postmenopausal 
women with osteoporosis receiving raloxifene showed 
significant increase in bone mineral density (BMD) and 
reduced incidence of subsequent vertebral fractures.[7‑11]
Raloxifene does not stimulate the endometrium of 
breast.[12,13] Osteoporosis is a major cause of morbidity 
worldwide[14,15] 
Therefore, it is important to investigate therapies 
for prevention and treatment of osteoporosis in 
postmenopausal women. Previous studies, suggest that 
long term use of raloxifene has favorable effect on serum 
lipid.[7,10,16] So, this study was designed to detect the effect 
of raloxifene hydrochloride on BMD and serum lipids in 
Kuwaiti postmenopausal women with osteoporosis.
SUBJECTS AND METHODS
Randomly selected eighty postmenopausal women, 
who received raloxifene 60 mg (Eli Lilly and Company, 
Indianapolis, USA) with calcium 500 mg and 200 IU Vitamin 
D daily for 2 years were included in this prospective study 
after informed consent, approval of the study by hospital 
ethical committee to compare changes in lumbar spine, 
total hip BMD and serum lipids before and after raloxifene 
treatment.
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Postmenopausal women free of severe or chronically 
disabling conditions, had their last menstrual period at least 
2 years before start of raloxifene, had a T‑score for femoral 
neck or lumbar spine BMD measurements ≤ 2.5, without 
previous treatment affecting BMD or affecting serum lipids, 
without fractures were included in this study.
Postmenopausal women with abnormal uterine bleeding, 
suspected, or history of carcinoma of the breast or 
estrogen‑dependent neoplasia as endometrial cancer, 
history of cancer within the previous 5 years, history 
of deep venous thrombosis, bone disorders other than 
osteoporosis, treatment with any medications affecting 
bone metabolism, liver diseases, impaired kidney functions 
were excluded from this study.[1]
Bone mineral density was measured by DXA using 
Hologic QDR‑2000 to test 4 sites (L1‑L4) of the lumbar 
spine at a posterio‑anterial position and 4 sites of the 
left hip (femoral neck, Ward`s triangle, trochanter, 
and intertrochanter) by radiologist who was blinded to 
patient`s data. Serum lipids including; total cholesterol, 
high‑density lipoprotein cholesterol (HDL‑C), low‑density 
lipoprotein cholesterol (LDL‑C) and triglycerides were 
also assessed before and after raloxifene treatment. 
Outcome measures changes in lumbar spine, total 
hip BMD and serum lipids before and after raloxifene 
treatment.
Sample size justification
The required sample size was calculated using G* Power 
software version 3.17 for sample size calculation (*Heinrich 
Heine Universität, Düsseldorf, Germany), setting the 
α‑error probability at 0.05, power (1−βerror probability) 
at 0.95% and effective sample size (w) at 0.5. The effective 
size (w) was calculated as follows: 2w= X / N , Where X2 
is the Chi‑square test and N is the total sample size. The 
number of participants needed to produce a statistically 
acceptable figure was 80 women. Assuming a 10% drop 
during follows up process, and so the number of women 
included in the beginning of this study was 88 and it was 
completed with 80 women.
Statistical analysis
Data were collected, tabulated then statistically analyzed 
using the Statistical Package for Social Sciences computer 
software version 18 (Chicago, IL, USA). Numerical variables 
were presented as mean and standard deviation (±SD), 
while categorical variables were presented as number (n) 
and percentage (%). Unpaired t‑test was used to compare 
lumbar spine, total hip BMD and serum lipid values before 
and after raloxifene treatment. A difference with a P < 0.05 
was considered statistically significant.
RESULTS
Eighty eight women were included in the beginning of this 
study and it was completed with 80 women (5 women were 
lost during follow up visits and 3 women decided to stop 
raloxifene early after 2 months of administration because 
of its side effects). Mean age of the studied population was 
64.4 (6.5) years (range: 58.5‑68.5 years), mean weight 
was 56.2 (6.9) kg (range: 45.4‑62.5 kg), mean height was 
164.5 (3.1) cm (range: 157.5‑173.2 cm), mean body mass 
index was 23.7 (5.7) kg/m2 (range: 22.5‑28.5 kg/m2), mean 
years since menopause was 5.3 (7.6) (range: 2.5‑7.2 years) and 
33.75% (3/80) of the studied population were cigarette smoker.
Lumbar spine and total hip BMD were significantly increased 
from 0.92 (3.8) and − 0.83 (5.6); respectively before treatment 
to 3.21 (5.4) and 1.62 (7.4); respectively 2 years after 
treatment (P < 0.01 S (95% confidence interval [CI]; −3.74 
to − 0.83) and 0.01 (95% CI; −4.49 to − 0.40); respectively). 
Also, Ward`s triangle and trochanter BMD were significantly 
increased from − 1.53 (6.6) and − 1.4 (6.4); respectively 
to 4.84 (9.3) and 1.78 (8.5); respectively (P = 0.01 (95% 
CI; 5.82 to − 0.79) and < 0.01 (95% CI; −5.52 to − 0.83; 
respectively) [Table 1 and Figure 1].
Total cholesterol and LDL‑C were significantly decreased 
from 5.15 (4.5) to 3.82 (4.6) mmol/L; respectively before 
treatment to 3.57 (3.4) and 2.56 (3.7) mmol/L; respectively 
2 years after treatment (P = 0.01 (95% CI; 0.33‑2.82) and 
0.5 (95% CI; −0.04‑2.56); respectively). While, changes in 
HDL‑C and triglycerides after treatment were statistically 
insignificant [Table 2 and Figure 2].
Table 1: Lumbar spine, total hip bone mineral density of 
studied population before and after treatment





Lumbar spine 0.92 (3.8) 3.21 (5.4) 0.002**, (−3.74 to −0.83)
Total hip −0. 83 (5.6) 1.62 (7.4) 0.01**, (−4.49 to −0.40)
Femoral neck −0.62 (6.3) 1.25 (8.8) 0.12*, (−4.24 to −0.51)
Ward’s triangle 1.53 (6.6) 4.84 (9.3) 0.01**, (−5.82 to −0.79)
Trochanter −1. 4 (6.4) 1.78 (8.5) 0.008**, (−5.52 to −0.83)
*Nonsignificant; **Significant. Test used: Unpaired t‑test. BMD – Bone mineral density; 
CI – Confidence interval; SD – Standard deviation
Table 2: Lipids profile of studied population before and 
after treatment





Total cholesterol 5.15 (4.5) 3.57 (3.4) 0.01**, (0.33 to 2.82)
High‑density 
lipoprotein cholesterol
1.56 (2.5) 1.45 (3.3) 0.8*, (−0.80 to 1.02)
Low‑density 
lipoprotein cholesterol
3.82 (4.6) 2.56 (3.7) 0.5**, (−0.04 to 2.56)
Triglycerides 2.34 (6.1) 1.56 (5.60) 0.4*, (−1.04 to 2.60)
*Nonsignificant; **Significant. Test used: Unpaired t‑test. SD – Standard deviation; 
CI – Confidence interval
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Adverse effects recorded in this study over 2 years 
were; nasopharyngitis (18.75% (15/80) cases), muscle 
cramps (8.75% (7/80) cases), hot flushes (7.5% (6/80) cases), 
allergic dermatitis (6.25% (5/80) cases), diarrhea (3.75% (3/80) 
cases).
DISCUSSION
Eighty postmenopausal women, who received raloxifene 
60 mg with calcium 500 mg and 200 IU Vitamin D daily for 
2 years were included in this study. BMD and serum lipids 
were assessed before and after treatment to detect the 
effect of raloxifene on BMD and on serum lipids.
Lumbar spine and total hip BMD were significantly increased 
2 years after raloxifene treatment. Also, Ward`s triangle 
and trochanter BMD were significantly increased 2 years 
after raloxifene treatment in this study.
Liu et al., found that 12 months after treatment of 
postmenopausal women with raloxifene both lumbar spine 
and total hip BMD was increased significantly compared 
with the placebo (mean increase in lumbar spine BMD was 
3.3 (4.8) and mean increase in total hip BMD was 1.4 (4.8) in 
the raloxifene group).[1]
Similar increases in lumbar spine and total hip BMD 
have been observed in response to raloxifene treatment 
in other clinical trials in postmenopausal women with 
osteoporosis.[8,9,16]
Increased lumbar spine and total hip BMD 2 years after 
raloxifene treatment in this study add further support to the 
idea that raloxifene acts as an antiresorptive agent on the 
skeletal system, preserving bone mass and an efficacious 
treatment option for osteoporosis.
Also, Abdelazim et al. and Khan and Fortier, concluded 
that raloxifene reduces the risk of vertebral fracture in 
postmenopausal women with osteoporosis.[8,9]
Healthy postmenopausal women with a BMD T‑score at the 
lumbar spine or femoral neck between −1.0 and −2.5 
or clinical risk factors for osteoporosis were randomly 
assigned to one of five groups (bazedoxifene 10, 20, or 
40 mg/day, placebo, or raloxifene 60 mg/day) by Miller 
et al., to detect the efficacy and safety of three doses of 
bazedoxifene compared with placebo and raloxifene in 
prevention of postmenopausal osteoporosis.[17]
Miller et al., concluded that treatment with bazedoxifene 
as well as raloxifene prevented bone loss and reduced bone 
turnover and was generally well tolerated in postmenopausal 
women with normal/low BMD.[17]
Total cholesterol and LDL‑C were significantly decreased 
2 years after raloxifene treatment, while, changes in 
HDL‑C and triglycerides after treatment were statistically 
insignificant in this study. Naves‑Díaz et al., in their 
study to detect the effects of raloxifene on BMD, serum 
cholesterol concentrations and uterine endometrium in 
postmenopausal women concluded that long term use of 
raloxifene has favorable effect on serum lipid without a 
significant rise in triglyceride.[7]
Also, Oztas et al. and Grover‑Páez et al., in their studies 
concluded that the long term use of raloxifene has 
favorable effect on serum lipid without a significant rise in 
triglyceride.[10,16]
The effects of raloxifene on serum lipids may explain the 
decrease in cardiovascular events observed in a subset of 
women with increased risk for cardiovascular events in the 
MORE study.[11]
Figure 2: Serum lipids profile of studied population before and after 
treatment
Figure 1: Lumbar spine, total hip bone mineral density of studied 
population before and after treatment
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Lost women during follow up visits and discontinuation 
of raloxifene due to side effects were faced as limitations 
during conduction of this study. Adverse effects of raloxifene 
recorded in this study were; nasopharyngitis, muscle 
cramps, hot flushes, allergic dermatitis, diarrhea, and were 
similar to adverse effects with recorded by Abdelazim et al. 
and Khan and Fortier, in their studies.[8,9]
The safety profile of raloxifene was confirmed by Naves‑Díaz 
et al., Abdelazim et al., and Oztas et al.,[7,8,10] also, in this 
study, the continuous use of raloxifene for 2 years by 
Kuwaiti postmenopausal women with osteoporosis was 
well tolerated without any serious side effects.
Osteoporosis is skeletal disease characterized by decrease 
bone mineralization and increase bone fragility with 
subsequent increased risk of fractures.[18] Osteoporosis is 
currently a major cause of mortality, morbidity, and medical 
expense worldwide.
In this study, raloxifene increases lumbar spine, total hip, 
Ward`s triangle, trochanter BMD and decreases total 
cholesterol and LDL‑C. Zheng et al., previously concluded 
that raloxifene increases lumbar spine and hip BMD 
in healthy postmenopausal women,[15] also, Liu et al., 
concluded that raloxifene increases lumbar spine, hip BMD 
and decreases biochemical markers of bone metabolism 
in postmenopausal women with osteoporosis, indicating 
that raloxifene provides an effective for the prevention and 
treatment of osteoporosis.[1]
Raloxifene appears to be an effective, well tolerated option 
for treating osteoporosis in Kuwaiti postmenopausal 
women, suitable for long term use with favorable effect on 
serum lipid profiles.
Large case controlled studies are needed to detect effect 
of raloxifene (cases) compared to control cases (not under 
effect of raloxifene) on BMD and serum lipids profile.
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